Form FWP KINDER MORGAN, INC. Filed by: KINDER MORGAN, INC.
- European stocks get tech lift, UBS climbs on naming Ermotti as CEO
- Lululemon surges 15% on earnings, guidance beat; Stifel says shares still 'undervalued'
- UBS brings back Sergio Ermotti as CEO to oversee Credit Suisse takeover
- Micron Q2 results fall short of estimates amid weaker demand
- Oil gains for 3rd day on Kurdish supply concern, easing banking fears
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Filed Pursuant to Rule 433
Registration File No. 333-240108
January 26, 2023
Pricing Term Sheet
$1,500,000,000 5.200% Senior Notes due 2033
|Issuer:||Kinder Morgan, Inc.|
|Ratings: (Moody’s / S&P / Fitch)*:||Baa2 / BBB / BBB|
|Ratings Outlooks: (Moody’s / S&P / Fitch)*:||Stable / Stable / Stable|
|Security Type:||Senior Notes|
|Pricing Date:||January 26, 2023|
|Settlement Date (T+3):||January 31, 2023|
|Interest Payment Dates:||June 1 and December 1, commencing June 1, 2023|
|Record Dates:||May 15 and November 15|
|Maturity Date:||June 1, 2033|
|Benchmark Treasury:||4.125% due November 15, 2032|
|Benchmark Treasury Price / Yield:||105-07 / 3.491%|
|Spread to Benchmark Treasury:||+175 bps|
|Yield to Maturity:||5.241%|
|Price to the Public:||99.683% of the aggregate principal amount|
|Optional Redemption:||Prior to March 1, 2033 (three months prior to the maturity date of the notes) (the “Par Call Date”), we may redeem the notes at our option, in whole or in part, at any time and from time to time, at a redemption price equal to the greater of: (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming such notes matured on the Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 30 basis points, less (b) interest accrued to the date of redemption, and (2) 100% of the principal amount of the notes being redeemed, plus, in either case, accrued and unpaid interest thereon to, but excluding, the redemption date.|
|On or after the Par Call Date, we may redeem the notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the notes being redeemed plus accrued and unpaid interest thereon to, but excluding, the redemption date.|
|CUSIP / ISIN:||49456B AX9 / US49456BAX91|
|Joint Book-Running Managers:||
Barclays Capital Inc.
J.P. Morgan Securities LLC
PNC Capital Markets LLC
Scotia Capital (USA) Inc.
BMO Capital Markets Corp.
ING Financial Markets LLC
Mizuho Securities USA LLC
SMBC Nikko Securities America, Inc.
Truist Securities, Inc.
Wells Fargo Securities, LLC
* Note: The ratings of a security are not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
The issuer has filed a registration statement (including a preliminary prospectus supplement and a prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement for this offering, the issuer’s prospectus in that registration statement and any other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by searching the SEC online data base (EDGAR) on the SEC web site at http://www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus supplement and prospectus if you request it by contacting Barclays Capital Inc. at 1-888-603-5847, J.P. Morgan Securities LLC at 1-212-834-4533, PNC Capital Markets LLC at 1-855-881-0697 or Scotia Capital (USA) Inc. at 1-800-372-3930.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Technip Energies Convenes its 2023 Annual General Meeting
- P2 Gold Gabbs Update
- Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!